1. US Food & Drug Administration. FDA grants accelerated approval to bosutinib for treatment of newly-diagnosed PH+ CML. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-bosutinib-treatment-newly-diagnosed-ph-cml. Accessed 24 October 2023.
2. European Medicines Agency. Bosulif (bosutinib) product information. https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif. Accessed 23 October 2023.
3. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib;Cortes;Blood,2011
4. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib;Cortes;Am J Hematol,2016
5. Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial;Gambacorti-Passerini;Blood,2021